Oppenheimer Upgrades Milestone to Outperform on 'Best-Case' FDA Outcome By: TalkMarkets July 29, 2020 at 09:31 AM EDT Oppenheimer analyst Leland Gershell upgraded Milestone Pharmaceuticals to Outperform from Perform with an $18 price target. Read More >> Related Stocks: Milestone Pharmaceuticals Inc